“CJC-1295” Does Not Always Mean the Same Molecule
Search CJC-1295, and one problem appears immediately:
Some pages describe a long-acting peptide that remains active for days.
Others describe a short-acting “No DAC” material.
They are not interchangeable.
CJC-1295 with DAC contains a Drug Affinity Complex modification designed to interact with circulating albumin and substantially extend the molecule’s exposure.
For professional researchers, that makes molecular identity especially important.
If the DAC modification changes the pharmacokinetics, the supplier must be able to prove which molecule is actually in the batch.
What Is CJC-1295 with DAC?
CJC-1295 with DAC, also known as CJC-1295 DAC or DAC:GRF, is a synthetic long-acting analog of growth hormone-releasing hormone (GHRH).
Research applications include:
- GHRH receptor signaling;
- GH/IGF-1 axis research;
- peptide pharmacokinetics;
- peptide–protein interactions;
- long-acting peptide design;
- analytical characterization.
Unlike the material commonly marketed as CJC-1295 No DAC / Modified GRF 1-29, the DAC-containing peptide incorporates a chemical modification that alters its biological persistence.
That distinction is not merely marketing terminology.
It is part of the molecule.
What Does the Human Research Actually Show?
CJC-1295 with DAC has limited but real human pharmacology data.
In randomized, placebo-controlled studies in healthy adults, CJC-1295 produced sustained, dose-dependent increases in GH and IGF-I. The estimated half-life was approximately 5.8–8.1 days, and multiple administrations produced a cumulative pharmacodynamic effect.
This makes CJC-1295 scientifically interesting as a long-acting GHRH analog.
But the distinction between biomarkers and clinical outcomes is essential.
Those early studies do not establish that CJC-1295 is clinically proven for:
- muscle building;
- fat loss;
- anti-aging;
- athletic recovery;
- sleep improvement;
- performance enhancement.
The published human evidence is mainly pharmacokinetic and endocrine.
Positive Data Do Not Eliminate the Safety Gap
Early studies described CJC-1295 as relatively well tolerated in the tested populations, with no serious adverse reactions reported in the published Phase 1 studies.
However, FDA’s later review noted that injection-site reactions were the most frequently reported adverse events, sometimes involving pain, swelling, induration or local urticaria. Flushing and other reactions were also documented.
Most importantly, the human evidence base remains small.
Short early-phase exposure cannot establish long-term safety.
For scientific buyers, limited evidence should be described as limited evidence—not converted into a safety guarantee.
Online Reviews Show Why Identity Matters
Community discussions about CJC-1295 DAC contain strongly positive and negative anecdotes.
Some users describe perceived improvements in recovery or energy.
Others report:
- flushing;
- headaches;
- itching;
- swelling;
- local lumps;
- uncomfortable injection-site reactions.
These anecdotes cannot establish clinical efficacy or causality.
But they reveal another problem that matters to research procurement:
Was the material really CJC-1295 with DAC—and was the batch properly characterized?
CJC-1295 with DAC vs No DAC: The Label Must Be Clear
One of the most persistent search problems is confusion between the two variants.
CJC-1295 with DAC is the long-acting DAC-containing molecule.
“CJC-1295 No DAC” is commonly used commercially for Modified GRF 1-29, which lacks the DAC modification and has a substantially different evidence base. A recent review notes that controlled human studies directly evaluating the No-DAC material are essentially absent.
That means a supplier should never leave the DAC status ambiguous.
For analytical research:
“CJC-1295” alone is not specific enough.
What Should Buyers Verify in a CJC-1295 DAC Supplier?
Professional laboratories should evaluate more than a headline purity percentage.
Useful questions include:
Identity
Is the material specifically identified as CJC-1295 with DAC?
CAS & Molecular Information
Does the documented CAS number, formula and molecular mass correspond to the DAC-containing compound?
HPLC Purity
Is chromatographic purity linked to the current batch?
Mass Spectrometry
Is molecular identity supported by MS data where specified?
Batch-Specific COA
Does the certificate correspond to the actual production lot?
Traceability
Can the supplied material be traced to the analytical documentation?
Current supplier practices increasingly emphasize this lot-specific approach; for example, current CJC-1295 DAC COAs in the market publish both HPLC purity and MS identity tied to an individual source batch.
SUNONE CJC-1295 with DAC Research Peptide
SUNONE supplies CJC-1295 with DAC / CJC-1295 DAC for qualified laboratory, analytical and biopharmaceutical research.
Current SUNONE specifications list:
- CAS 446262-90-4;
- molecular formula C165H269N47O46;
- molecular weight approximately 3647.2 g/mol;
- ≥98% HPLC;
- lyophilized research material;
- batch-specific COA availability;
- HPLC documentation;
- MS identity documentation according to batch specification;
- SDS and Specification Sheet;
- OEM/ODM and bulk B2B support.
Looking for a CJC-1295 with DAC Supplier?
For biotechnology companies, peptide laboratories and research distributors, the purchasing question should not simply be:
“Do you have CJC-1295?”
A better question is:
“Is it the DAC-containing molecule, and can the analytical documentation verify that?”
If your organization is evaluating CJC-1295 with DAC, CJC-1295 DAC, DAC:GRF or other long-acting GHRH research peptides, contact SUNONE for current specifications, batch documentation, MOQ, packaging, OEM/ODM information and quotation support.
Conclusion
The DAC modification is not a minor naming detail.
It is central to what makes CJC-1295 a long-acting research peptide.
That means serious procurement should verify:
DAC status, molecular identity, HPLC purity, MS data and batch-specific documentation.
For CJC-1295 research, the most important question is not:
“How long does it last?”
It is:
“Can the supplier prove which molecule produced the data?”
This content is provided for scientific and educational purposes only. SUNONE research peptide is for qualified labrtorynt, diagnois, druc tor mmatct or veteimant, use.research only, Not for human consumption, clinical treame. Purchasers are responsible for complying with applicable laws and regulations in their jurisdiction.
Leave a Reply